Evidence of CAR T-cell therapy against cancers presented at US conference
CAR T-cell therapy
against gastric and brain tumours.
The papers, presented at the annual meeting of the American Society of Clinical Oncology [ASCO] 2025, held from May 30 to June 3 in Chicago, US, have also been published in journals, including The Lancet and Nature Medicine.
Treating cancer using CAR T-cell therapy involves modifying genes in one's T-cells - a type of immune cell - to help fight cancer.
In The Lancet paper, that revealed results of phase 2
clinical trials
, 156 patients with advanced gastric or gastro-oesophageal junction cancer - and who were resistant to "at least two previous lines of treatment" - were randomly assigned to receive 'satri-cel' or an intervention of physician's choice.
Satri-cel, or 'Satricabtagene autoleucel' - a CAR T-cell therapy -- showed "encouraging activity" in phase 1 clinical trials in treating patients with advanced gastric or gastro-oesophageal junction cancer, the team, including researchers from China's Peking University Cancer Hospital and Institute, said.
A phase-1 trial primarily looks at establishing a new drug's safety and dose characteristics in about 20-100 healthy volunteers, while a 'phase-2' trial provides evidence of the effectiveness of the experimental drug in about 100-300 volunteers or participants.
"In this multicentre, randomised, phase 2 study, satri-cel was associated with a statistically significant increase in progression-free survival and clinically meaningful increase in overall survival compared with TPC (treatment of physician's choice), along with a manageable safety profile in patients," the authors wrote.
They added that it is the "first randomised controlled study of a CAR T-cell therapy in solid tumours".
In the second study, published in the Nature Medicine journal, researchers from the University of Pennsylvania, US, said that CAR T-cell therapy "shows promise for slowing tumour growth in a notoriously aggressive and fast-growing
brain cancer
".
The phase-1 trial involved 18 patients with
glioblastoma
who received the treatment.
"Tumour regression (becoming smaller) occurred in eight of 13 patients (62 per cent) with measurable disease," the authors wrote.
In March, a CAR T-cell therapy, indigenously developed by researchers from the Indian Institute of Technology-Bombay and Tata Memorial Hospital, Mumbai, showed a 73 per cent response rate in patients of leukaemia and lymphoma, who either relapsed following a period of remission or were resistant to treatment.
The results of the phase 1 and 2 clinical trials are published in The Lancet Haematology journal. PTI
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Hindustan Times
a day ago
- Hindustan Times
In new study, AI decodes fitness trackers for top health advice
On most mornings, your fitness tracker greets you with a string of numbers — steps taken, hours slept, heart rate, maybe a 'sleep score' out of 100. But what if those numbers came with the kind of nuanced, tailored advice you'd expect from a personal coach who knows the science inside out? That's the vision behind PH-LLM, a new AI system unveiled by Google researchers in 2024. PH-LLM also predicted how users would rate their own sleep quality from wearable data alone — a capability traditional trackers generally lack. In a study published in the journal Nature Medicine on Thursday, the company's researchers reported that its personal health coaching can interpret wearable device data and match — or even surpass — human experts in sleep and fitness advice. The system, called the Personal Health Large Language Model (PH-LLM), is a fine-tuned version of Google's Gemini AI trained to understand daily sensor readings from devices such as smartwatches and fitness trackers like Apple Watch and Fitbit. In the study, PH-LLM outperformed domain experts on professional exam questions and provided individualised insights that human evaluators rated nearly on par with specialist-written recommendations. The study found PH-LLM could score 79% on sleep medicine questions and 88% on fitness questions, beating expert averages of 76 and 71%. In more than 850 case studies using real-world data, the AI's sleep and fitness recommendations were rated almost as highly as those of human specialists, with notable gains over the base Gemini model for sleep-specific insights. PH-LLM also predicted how users would rate their own sleep quality from wearable data alone — a capability traditional trackers generally lack. The authors, however, caution that PH-LLM is not yet ready for consumer release. It occasionally introduces errors or assumptions, and its training data does not represent all populations. Next steps will include testing with more diverse users, integrating richer time-series sensor data, and studying whether people follow and benefit from the model's advice. 'These are interesting developments. Smart wearable devices help understand physiological factors / pathological aspect. Thus, the data may help professionals to guide/counsel individuals to handle some health concerns, but this area is growing and we need to learn more and also its limitations. Proper and precise interpretation of data is important for its precise use,' said Dr KK Talwar, former head of cardiology, AIIMS, Delhi. Dr Talwar stressed that insights from such devices must be used with expert advice for accurate interpretation and advice for now. 'Because of its simplicity, some individual may use and draw inaccurate interpretations that lead to health stress and unnecessary obsession. Obsession is itself a stress and may affect individual health with self-use of such smart devices,' he cautioned. 'This paper shows that personalised advice by AI would become a reality soon. It can go beyond generic advice to provide actionable insights from wearable devices. For India, with its diverse population and growing lifestyle-related conditions, this technology holds immense promise. It can empower millions of Indians with lifestyle-related diseases to take control of their sleep and fitness,' said Dr Anoop Misra, chairman, Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology. To make it work, the company trained PH-LLM in two stages: First, it learned from hundreds of detailed case studies pairing demographic information and up to 30 days of aggregated wearable metrics with expert-written advice for improving sleep or fitness. Second, they added a 'multimodal adapter' that converted numerical sensor data — such as heart rate variability, sleep stages and activity minutes — into a format the AI could process like text. This enabled the model to connect specific data patterns to targeted recommendations.
Time of India
3 days ago
- Time of India
Lab-grown rabies antibodies show promise as cheaper, safer alternative
Mumbai: India's public hospitals and dispensaries may soon have a safer, more affordable option for preventing rabies after a suspected rabid dog bite: one already in use in private clinics since 2017 and by BMC since 2019. A post-marketing clinical trial involving more than 4,000 participants, conducted and funded by a pharmaceutical company and recently published in The Lancet, could now pave the way for its large-scale public use. For decades, the life-saving protocol has been the same across public or private health set ups: wash the wound, inject a dose of rabies immunoglobulin if the bite is severe, and follow with multiple doses of anti-rabies vaccine. The possible shift lies in the kind of immunoglobulin used. The relatively new lab-made candidate could replace the animal and human derived versions in use since the 1970s. An immunoglobulin is a concentrated solution of antibodies, injected directly into and around the bite, that offers immediate but short-term protection against the virus, effectively buying time until the vaccine takes full effect. The earliest ones in use have been derived either from rabies-vaccinated horses (Equine Rabies Immunoglobulin - ERIG) or human donated plasma (Human Rabies Immunoglobulin - HRIG). by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo In 2016, Serum Institute of India (SII) received permission to make immunoglobulin which has monoclonal (lab-made,RmAb) antibodies. You Can Also Check: Mumbai AQI | Weather in Mumbai | Bank Holidays in Mumbai | Public Holidays in Mumbai | Gold Rates Today in Mumbai | Silver Rates Today in Mumbai "Most private facilities at least in Mumbai have phased out the use of the horse-derived one. While it has been proven safe at large, there are risks associated; it can cause mild allergic reactions or in rare cases a serious adverse event," said Dr Trupti Gilada, city-based infectious disease specialist. The private facilities have moved on to either the human derived or lab-made ones. "Both, human derived one and the lab-made one have high efficacy. The former has risk of infection transmission, though rare. The ones made in labs are safer and more easily available due to ease of largescale production," said Dr Mandar Kubal, another infectious disease specialist. A survey by ICMR published in July on the availability of anti-rabies vaccine and rabies immunoglobulin in health facilities found that, of the 534 facilities surveyed across 15 states and 60 districts -- 467 in the public sector -- 78% still used horse derived immunoglobulin. But even that was out of stock for most apart from a small 20.3% of those surveyed. While BMC uses the lab-made alternative, it is no stranger to shortages; at the moment it is short of rabies vaccine shots. A senior doctor from one of the four BMC-run medical college hospitals, said, "Mumbai has a heavy burden of dog bite cases and early on BMC decided to move on from animal derived ones due to risks associated. We either use generic human derived immunoglobulin or largely lab-made alternatives." But this lab-made alternative is still to make its way into the National Guidelines for Rabies Prophylaxis. The ICMR survey states, "RmAb presents as a promising alternative to both HRIG and ERIG. Compared to ERIG, RmAb offers the potential scope for large-scale production with standardised quality, elimination of animal use in the manufacturing, and reduced risk of adverse events. "It is cheaper compared to HRIG. Studies have shown that RmAbs are safe for human use, but... [there is] need for larger clinical trials and post-marketing surveillance to assess the safety and efficacy of RmAbs in the Indian setting." The Serum Institute–funded post marketing trial of its lab-made product compared with horse-derived immunoglobulin found to be equally effective in preventing rabies, with slightly higher average antibody levels on day 14. It was linked to fewer mild adverse events (11 vs. 17), and no serious reactions related to RmAb were reported, compared with one serious reaction related to ERIG. "Anti-rabies vaccines and immunoglobulins are severely in shortage across the country. Monoclonal antibodies is the answer [due to scalability] and it needs to be included in the national guidelines," said one of the authors of the ICMR survey. Stay updated with the latest local news from your city on Times of India (TOI). Check upcoming bank holidays , public holidays , and current gold rates and silver prices in your area.
Time of India
3 days ago
- Time of India
Lab-grown rabies antibodies show promise as safe alternative
MUMBAI: India's public hospitals and dispensaries may soon have a safer, more affordable option for preventing rabies after a suspected rabid dog bite: one already in use in private clinics since 2017 and by BMC since 2019. Tired of too many ads? go ad free now A post-marketing clinical trial involving more than 4,000 participants, conducted and funded by a pharmaceutical company and recently published in The Lancet, could now pave the way for its large-scale public use. For decades, the life-saving protocol has been the same across public or private health set ups: wash the wound, inject a dose of rabies immunoglobulin if the bite is severe, and follow with multiple doses of anti-rabies vaccine. The possible shift lies in the kind of immunoglobulin used. The relatively new lab-made candidate could replace the animal and human derived versions in use since the 1970s. An immunoglobulin is a concentrated solution of antibodies, injected directly into and around the bite, that offers immediate but short-term protection against the virus, effectively buying time until the vaccine takes full effect. The earliest ones in use were derived either from rabies-vaccinated horses (Equine Rabies Immunoglobulin - ERIG) or human donated plasma (Human Rabies Immunoglobulin - HRIG). In 2016, (SII) received permission to make immunoglobulin which has monoclonal (lab-made,RmAb) antibodies. "Most private facilities at least in Mumbai have phased out the use of the horse-derived one. While it has been proven safe at large, there are risks associated; it can cause mild allergic reactions or in rare cases a serious adverse event," said Dr Trupti Gilada, city-based infectious disease specialist. The private facilities have moved on to either the human derived or lab-made ones. "Both, human derived one and the lab-made one have high efficacy. Tired of too many ads? go ad free now The former has risk of infection transmission, though rare. The ones made in labs are safer and more easily available due to ease of largescale production," said Dr Mandar Kubal, another infectious disease specialist. A survey by ICMR published in July on the availability of anti-rabies vaccine and rabies immunoglobulin in health facilities found that, of the 534 facilities surveyed across 15 states and 60 districts -- 467 in the public sector -- 78% still used horse derived immunoglobulin. But even that was out of stock for most apart from a small 20.3% of those surveyed. While BMC uses the lab-made alternative, it is no stranger to shortages; at the moment it is short of rabies vaccine shots. A doctor from one of the four BMC-run medical college hospitals, said, "Mumbai has a heavy burden of dog bite cases and early on BMC decided to move on from animal derived ones due to risks associated. We either use generic human derived immunoglobulin or largely lab-made alternatives." But this lab-made alternative is still to make its way into National Guidelines for Rabies Prophylaxis. The ICMR survey states, "RmAb presents as a promising alternative to both HRIG and ERIG. Compared to ERIG, RmAb offers the potential scope for large-scale production with standardised quality, elimination of animal use in the manufacturing, & reduced risk of adverse events. "It is cheaper compared to HRIG. Studies have shown that RmAbs are safe for human use, but... [there is] a need for larger clinical trials and post-marketing surveillance to assess the safety and efficacy of RmAbs in the Indian setting." The Serum Institute-funded post marketing trial of its lab-made product compared with horse-derived immunoglobulin found to be equally effective in preventing rabies, with slightly higher average antibody levels on day 14.
